| Identification | Back Directory | [Name]
9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- | [CAS]
714971-87-6 | [Synonyms]
Ro0711401
9H-Xanthene-9-carboxamide, N-[4-(trifluoromethyl)-2-oxazolyl]- | [Molecular Formula]
C18H11F3N2O3 | [MDL Number]
MFCD31692711 | [MOL File]
714971-87-6.mol | [Molecular Weight]
360.29 |
| Chemical Properties | Back Directory | [density ]
1.469±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (277.55 mM; Need ultrasonic) | [form ]
Solid | [pka]
11.52±0.20(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM[1][2]. | [Biological Activity]
RO0711401 is a selective and orally active positive allosteric modulator of mGlu1 receptor with an EC50 of 56 nM[1][2].
RO0711401 (10 mg/kg; s.c.; once) causes a long-lasting improvement in motor performance, which is maintained to the same extent at least for 6 days[1].Systemic injection of RO0711401 is shown to reduce the frequency of spike-and-wave discharges in a rat model of absence epilepsy, and to improve motor signs in autoimmune encephalomyelitis (EAE) mice[1]. | [in vivo]
RO0711401 (10 mg/kg; s.c.; once) causes a long-lasting improvement in motor performance, which is maintained to the same extent at least for 6 days[1].
Systemic injection of RO0711401 is shown to reduce the frequency of spike-and-wave discharges in a rat model of absence epilepsy, and to improve motor signs in autoimmune encephalomyelitis (EAE) mice[1]. | Animal Model: | Spinocerebellar ataxia type 1 (SCA1) mice (30-week old)[1] | | Dosage: | 10 mg/kg | | Administration: | Subcutaneous injection; once | | Result: | Caused a prolonged improvement of motor performance on the rotarod and the paw-print tests. |
| [IC 50]
mGluR1: 56 nM (EC50) | [References]
[1]. Serena Notartomaso, et al. Pharmacological enhancement of mGlu1 metabotropic glutamate receptors causes a prolonged symptomatic benefit in a mouse model of spinocerebellar ataxia type 1. Mol Brain. 2013 Nov 19;6:48. [2]. Eric Vieira, et al. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers. Bioorg Med Chem Lett. 2009 Mar 15;19(6):1666-9. |
|
|